Fund manager John Bennett has embarked on a new direction in an effort to revamp the Henderson European Focus Trust (LSE: HEFT).
"We have moved to take more active sector positions against the benchmark in order to differentiate ourselves from other passive strategies in the market, albeit at the expense of greater volatility," Bennett told Investment Week.
The trust, which has returned 8% over five years, or 21% over three years, had to adapt to survive, says Bennett, manager since December 2010. It currently trades at a 14% discount to its net asset value. Bennett has halved the trust's holdings to create a more concentrated portfolio, underweight in financials, utilities and telecommunications. He expects a ten-year bear market for the banks.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The £90.4m trust has large holdings in healthcare and pharmaceuticals, the latter currently at 20.5%. However, Bennett told Fund Strategy that this could rise to 30%. Despite concerns over patent expiries, drug failures and regulation, he remains optimistic: "Science has not gone away," he says. "Today they do not need to find a single new drug to make money out of pharmaceuticals. Why? Because they are not priced to find new drugs."
Bennett expects companies to bolster cash flow by targeting markets where constant drug innovation is unnecessary, such as generic drugs, nutritional foods, animal health and emerging markets. Companies could still discover blockbusters, but "we as shareholders are not asked to pay a premium for that. We are just buying their cash flow."
Contact: 0800-856 5656.
Henderson European Focus Trusttop ten holdings
| Nestl | 5.2% |
| Roche | 4.5% |
| Novartis | 4.3% |
| Sanofi | 4.1% |
| Total | 3.9% |
| Elekta | 3.6% |
| Reed Elsevier | 3.5% |
| SAP | 3.1% |
| Henkel | 3.1% |
| Rexel | 2.2% |
-
8 of the best converted properties for sale nowThe best converted properties for sale – from an apartment in the former Hartley’s Jam factory on London’s Southbank, to a converted 18th-century mill in Itteringham, Norfolk
-
How taking a two-year career break could leave a £26k hole in your pensionCareer breaks are increasingly common but it is important to take steps to protect your pension, as gaps compound over time
